Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Gene Editing
Sort By
Newest First
1 / 2
1 / 2
CASGEVY
Orsini Now Distributing CASGEVY® (exagamglogene autotemcel), a Gene-Editing Therapy
Orsini Healthcare
PR-11-24-NI-103
Nov 15, 2024
CRISPR
The Groundbreaking Potential of CRISPR Gene Editing
Olivia Newton-John Cancer Research Institute
PAO-10-24-RTM-09
Nov 05, 2024
Gene Editing
MegaBulb DNA: a Non-Viral ssDNA Breakthrough Revolutionizing Gene Editing
Tom Adie, Ph.D.; Elena Stoyanova, Ph.D.
Touchlight
PAO-10-24-CL-01
Sep 30, 2024
Lipid Nanoparticle Development
Lipid Technology for Delivery of Gene-Editing Therapies
Stephen Burgess, Ph.D.
Croda Pharma
PAO-11-022-CL-18
Jan 17, 2023
Antibiotic Resistance
Antibiotic Resistance: Advances in Understanding and Drug Development
David Alvaro, Ph.D.
Pharma's Almanac
PAO-10-022-NI-07
Oct 11, 2022
mRNA
Limitless Potential of mRNA Creates Tremendous Excitement Despite Uncertainties
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-10-022-NI-02
Oct 11, 2022
CRISPR Research Innovation
A Cellular Engineering Breakthrough: High-Yield CRISPR Without Viral Vectors
Gladstone Institutes
PR-M08-22-05
Aug 25, 2022
Regulatory
FDA Makes Low-Risk Determination for Marketing of Products from Genome-Edited Beef Cattle After Safety Review
U.S. Food & Drug Administration
PR-M03-22-03
Mar 07, 2022
Gene Editing
Prime Medicine Launches with $315 Million Financing to Deliver on the Promise of Prime Editing
Prime Medicine
PA852
Jul 16, 2021
Gene Editing
Enabling Gene-Edited hMSCs with a Fit-for-Purpose Transduction Agent
David Alvaro, Ph.D.
Pharma's Almanac
PAO-07-21-CL-06
Jul 15, 2021
Collaboration
Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing
Vertex
PR-M04-21-024
Apr 22, 2021
Gene Editing
Enhancing Human Gut Tissue Models through Gene Editing
Scott Magness, Ph.D.
Altis Biosystems
PAO-11-20-CL-03
Nov 30, 2020
CRISPR RNPs
CRISPR RNPs and the Future of Cell and Gene Therapy
Thomas Lynch, Ph.D.
Aldevron
PAP-Q3-20-CL-002
Sep 29, 2020
Gene Therapy
Slow Progress and a Shaky Start—What’s Next for Gene Therapy?
Nigel Walker
Nice Insight
PAP-Q4-19-NI-001
Dec 06, 2019
CRISPR-Cas9
CRISPR-Cas9 Milestones: The First In Vivo Clinical Trial Is Now Underway
Lydia Michaut
BioAgilytix
PAP-Q4-19-CL-011
Dec 06, 2019
CRISPR
CRISPR Gene Editing of Babies Could Take Place in Russia
Emilie Branch
Pharma's Almanac
PAO-M06-19-NI-021
Jun 21, 2019
Gene Editing
China to Introduce Regulations on Gene Editing
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-M05-19-NI-031
May 29, 2019
CRISPR-Cas9
University of California Granted New CRISPR-Cas9 Patent, Extending its Patent Portfolio for Genome Editing
The University of California
PR-M03-19-NI-040
Mar 14, 2019
Cell and Gene Therapy
Precision BioSciences Aims for Significant Funding Support based on its ARCUS Gene Editing Tech
David Alvaro, Ph.D.
Pharma's Almanac
PAO-M03-19-NI-013
Mar 05, 2019
Genome Editing
Sangamo Announces Interim Results Of Phase 1/2 CHAMPIONS Study Showing Preliminary Evidence Of In Vivo Genome Editing In Patients With MPS II Treated With SB-913
Sangamo Therapeutics
PR-M02-19-NI-020
Feb 11, 2019
